Latest News and Press Releases

- Data demonstrated that oat avenanthramides supplementation could inhibit molecules involved in the exercise induced inflammation process EDMONTON, Alberta, June 05, 2019 (GLOBE NEWSWIRE) --...

– Ceapro at the forefront of pioneering approach with a natural product as add-on therapy to a prescription product – Study evaluating the well-known health claims of beta glucan and its potentially...

- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development of delivery systems - ...

EDMONTON, Alberta, May 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...

EDMONTON, Alberta, April 24, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...

EDMONTON, Alberta, April 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...

– 2018 marked by Company’s catalytic pivot from contract manufacturer tobiopharmaceutical company and validation of Ceapro’s dedication to innovation – EDMONTON, Alberta, April 11, 2019 (GLOBE...

EDMONTON, Alberta, March 27, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...

EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...

EDMONTON, Alberta, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...